Ibnsina Pharma (ISPH) reported a 45.16% year-on-year (YoY) decrease in its consolidated net profits after tax and non-controlling interests for the full year ended December 31st, 2022, according to the company’s financial statements filed to the Egyptian Exchange (EGX) on March 1st.

The company’s consolidated net profit after minority interest stood at EGP 172.584 million in 2022, down from EGP 314.727 million in 2021.

Consolidated net revenue amounted to EGP 22.264 billion last year, compared with EGP 21.732 billion in 2021.

Meanwhile, the company’s standalone net profit after tax dropped to EGP 176.375 million in 2022 from EGP 315.655 million in 2021.

Ibnsina is an Egypt-based pharmaceutical distribution company, with a diversified portfolio of pharmaceutical products from over 350 Egyptian and multinational companies to more than 35,000 customers including pharmacies, hospitals, retail outlets, and wholesalers.

 

Copyright © 2022 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).